Strengthening FDA Submission with New Data
Intelligent Bio Solutions Inc. (NASDAQ: INBS), a pioneering medical technology firm dedicated to innovative testing solutions, has announced an important advancement in its FDA 510(k) submission process. Recent data reinforces the outstanding performance of the Intelligent Fingerprinting Drug Screening System, specifically focusing on its ultra-precise ability to detect trace sweat volumes.
Innovative Technology and Rigorous Testing
The company’s state-of-the-art system has demonstrated remarkable resilience during extensive cybersecurity testing, ensuring its reliability across diverse operating conditions. Peter Passaris, the company’s Vice President of Product Development, emphasizes the productive engagement with the FDA as they prepare to submit their findings along with new data, showcasing their commitment to regulatory compliance.
Advanced Quantification Techniques
The advanced technology developed by Intelligent Bio Solutions enables the detection of minute volumes of sweat in a fingerprint, measured using the Ultra-Micro Balance scale. This sophisticated instrument provides insights down to 0.0000001 grams, showcasing the system's unparalleled precision in detecting even the smallest traces of substances, affirming the company’s capability in safe and effective drug testing.
A Focused Approach Towards FDA Clearance
As the resubmission deadline approaches, the leadership team at Intelligent Bio Solutions is diligently addressing the FDA's inquiries and refining their submission's quality. President and CEO Harry Simeonidis highlights the extensive collaboration with regulatory consultants and the company’s commitment to enhancing its submission, having amassed over 6,000 hours dedicated to testing and data analysis.
Meeting Growing Industry Demand
Intelligent Bio Solutions’ drug testing technology is poised to meet escalating demands in safety-critical industries. With over 450 accounts spanning 24 countries and 18 distribution partners, the company is strategically positioned for expansion. As they work toward obtaining FDA clearance for their opiate test for codeine, plans are also underway to penetrate the U.S. market, which is valued in the multi-billion-dollar range.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is at the forefront of medical technology, delivering results-driven, rapid, and non-invasive testing solutions. Their Intelligent Fingerprinting Drug Screening System is designed for high hygiene standards and efficiency, screening for recent drug use within minutes. It serves a broad array of sectors, from construction to transportation, ensuring workplace safety and compliance.
Future of Testing Solutions
With its innovative approach to drug testing, Intelligent Bio Solutions aims to revolutionize the landscape of portable testing technologies. As the company contemplates future applications for its flagship product, it remains committed to continuous improvement and advancing user-friendly drug testing solutions.
Frequently Asked Questions
What does Intelligent Bio Solutions specialize in?
Intelligent Bio Solutions specializes in innovative, rapid, and non-invasive drug testing solutions using fingerprint sweat analysis.
What recent data has the company collected?
The recent data accentuates the system's ability to detect minute sweat volumes and confirms its performance in diverse conditions.
What are the regulatory plans of Intelligent Bio Solutions?
The company is preparing to strengthen its FDA 510(k) submission by submitting new data and addressing the FDA's inquiries.
How does the Intelligent Fingerprinting Drug Screening System work?
The system analyzes fingerprint sweat to screen for common drugs of abuse, offering a hygienic and rapid testing method.
What markets does Intelligent Bio Solutions serve?
Intelligent Bio Solutions serves a variety of markets, including construction, manufacturing, transport, and drug treatment organizations, aiming to ensure workplace safety.
